Only one treatment is licensed for idiopathic pulmonary fibrosis and this only in Europe. Luca Richeldi (Center for Rare Lung Diseases, University of Modena, Italy) describes his phase 2 trial of a tyrosine kinase inhibitor to see if it could be safely and effectively used in patients with the disease. Dr Richeldi’s research was published in the New England Journal of Medicine.

See also:
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis